Thukkani Arun K, Kinlay Scott
From BJCMG Cardiology, Missouri Baptist Hospital, Saint Louis (A.K.T.); and Cardiovascular Divisions, VA Boston Healthcare System and Brigham and Women's Hospital, MA.
Circ Res. 2015 Apr 24;116(9):1599-613. doi: 10.1161/CIRCRESAHA.116.303503.
Advances in endovascular therapies during the past decade have broadened the options for treating peripheral vascular disease percutaneously. Endovascular treatment offers a lower risk alternative to open surgery in many patients with multiple comorbidities. Noninvasive physiological tests and arterial imaging precede an endovascular intervention and help localize the disease and plan the procedure. The timing and need for revascularization are broadly related to the 3 main clinical presentations of claudication, critical limb ischemia, and acute limb ischemia. Many patients with claudication can be treated by exercise and medical therapy. Endovascular procedures are considered when these fail to improve quality of life and function. In contrast, critical limb ischemia and acute limb ischemia threaten the limb and require more urgent revascularization. In general, endovascular treatments have greater long-term durability for aortoiliac disease than femoral popliteal disease. Infrapopliteal revascularization is generally reserved for critical and acute limb ischemia. Balloon angioplasty and stenting are the mainstays of endovascular therapy. New well-tested innovations include drug-eluting stents and drug-coated balloons. Adjunctive devices for crossing chronic total occlusions or debulking plaque with atherectomy are less rigorously studied and have niche roles. Patients receiving endovascular procedures need a structured surveillance plan for follow-up care. This includes intensive treatment of cardiovascular risk factors to prevent myocardial infarction and stroke, which are the main causes of death. Limb surveillance aims to identify restenosis and new disease beyond the intervened segments, both of which may jeopardize patency and lead to recurrent symptoms, functional impairment, or a threatened limb.
在过去十年中,血管内治疗的进展拓宽了经皮治疗外周血管疾病的选择。对于许多患有多种合并症的患者,血管内治疗提供了一种比开放手术风险更低的替代方案。在进行血管内干预之前,需进行非侵入性生理测试和动脉成像,以帮助定位疾病并规划手术。血运重建的时机和必要性与间歇性跛行、严重肢体缺血和急性肢体缺血这三种主要临床表现密切相关。许多间歇性跛行患者可通过运动和药物治疗。当这些方法无法改善生活质量和功能时,才考虑进行血管内手术。相比之下,严重肢体缺血和急性肢体缺血会威胁肢体,需要更紧急的血运重建。一般来说,血管内治疗对主髂动脉疾病的长期耐久性优于股腘动脉疾病。腘以下血运重建通常仅用于严重和急性肢体缺血。球囊血管成形术和支架置入术是血管内治疗的主要手段。经过充分测试的新创新包括药物洗脱支架和药物涂层球囊。用于穿过慢性完全闭塞或通过旋切术去除斑块的辅助装置研究较少,作用有限。接受血管内手术的患者需要一个结构化的监测计划进行后续护理。这包括强化治疗心血管危险因素以预防心肌梗死和中风,这两者是主要的死亡原因。肢体监测旨在识别干预节段以外的再狭窄和新疾病,这两者都可能危及通畅性并导致复发症状、功能障碍或肢体受到威胁。